Quick Menu

Upcoming Journals

British Biotechnology Journal

British Biotechnology Journal, ISSN: 2231-2927,Vol.: 8, Issue.: 4

Short Research Article

New Monoclonal Antibodies to Human IgA: Obtaining and Study of Biological Properties

 

Alexander Galkin1*, Alex Dugan1, Valentine Solovjova2 and Larisa Bondarenko3

1National Technical University of Ukraine, Kyiv Polytechnic Institute, 03056 Kyiv, Peremogy av., 37, Ukraine.

2Ukrainian Scientific and Research Institute of Nutrition, Biotechnology and Pharmacy, 01042 Kyiv, Chygorina str., 18, Ukraine.

3Institute of Pharmacology and Toxicology of National Academy of Medical Science of Ukraine, 03680 Kyiv, Eugene Pottier Str., 14, Ukraine.

 

Article Information
Editor(s):
(1) Chung-Jen Chiang, Department of Medical Laboratory Science and Biotechnology, China Medical University, Taiwan.
Reviewers:
(1) Anonymous, Canada.
(2) Anonymous, Universidade de S˜ao Paulo, Brazil.
(3) Anonymous, India.
(4) Anonymous, Fairleigh Dickinson University, USA.
Complete Peer review History: http://sciencedomain.org/review-history/10316

 

Abstracts

 

Aim: Preparation of monoclonal antibodies to human IgA, investigation of their properties and selection of the most appropriate McAbs for highly sensitive and specific immunoassay tests.

Methodology: Balb/c mice were used for monoclonal antibodies (McAbs) production. Animals were immunized subcutaneously with purified preparation of human IgA. Immunization duration - 7 days, B cells source - regional lymph nodes. Hybridization of immunocompetent cells and myeloma cells was performed with polyethylene glycol as a fusogen. Screening and subsequent hybridoma clones selection was performed by ELISA-test using human IgA and IgA Fc-fragments, IgG and human IgM. To determine the isotype of McAbs, titer, affinity constants, and to identify its comparative epitopic specificity appropriate modifications of ELISA-test were used.  

Results: In our experiments new hybrid clones selection scheme to define the most appropriate McAbs for highly sensitive and specific immunoassay tests was developed. It was established that the most prospective were hybridoma clones producing antibodies against Fc-region of IgA molecule. It was proposed to have a comprehensive description of antibodies, which included the establishment of its isotype, titer, and affinity constants. In view of the further use of obtained McAbs for development of highly informative immunoassay methods, only high titer and affinity antibodies were selected. Since IgM-antibodies are characterized by low specificity and affinity, McAbs of such isotype have not been chosen for further study. Focusing on more efficient McAbs purification on protein A based sorbents, antibodies with IgG2a, IgG2b, and IgG3 isotypes were selected. It was established that there is a correlation between the antibody titer in the culture fluid and its affinity constant: antibodies with titer more than 1:500 characterized by an affinity constant not less than 109 лю-1.

Conclusion: A set of 14 new monoclonal antibodies to human IgA has been obtained. Following biological properties of obtained McAbs has been studied: Activity in the indirect ELISA, specificity within IgA molecule (Fab- or Fc- fragment), cross-reactivity with other classes of serum immunoglobulins (human IgG, and IgM), titer in the culture fluid, affinity constant, and relative epitope specificity. Criteria of McAbs selection for their further use in highly sensitive and specific immunoassay methods have been developed. McAbs with following characteristics are the most promising for these purposes: they should  be directed to the Fc-fragment of IgA, have a high signal in the indirect ELISA, absence of cross-reactivity with other classes of immunoglobulins, titer in the culture fluid not less then 1:500, and affinity constant not less then 8.0×109 M-1. McAbs of IgM isotype  are not suitable for effective biotechnological approaches.

 

Keywords :

Monoclonal antibodies; hybridomas; human IgA; affinity; epitope mapping.

 

Full Article - PDF    Page 1-9    Article Metrics

 

DOI : 10.9734/BBJ/2015/18955

Review History    Comments

Search this site

Advanced Search

Announcement & News

Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and its editors

We are happy to inform that Nature (Impact Factor: 41.6) confirmed high standard of SDI journal and ...

ISI Thomson Reuters selected British Journal of Pharmaceutical Research for Emerging Sources Citation Index

We are delighted to inform that ISI Thomson Reuters selected British Journal of Pharmaceutical Resea...

SCOPUS selected Annual Research & Review in Biology (ARRB)

We are delighted to inform that famous indexing organization SCOPUS (from Elsevier) selected  A...

Index Copernicus Evaluation Result Released

We are delighted to inform that Index Copernicus (a leading indexing organization from Pol...

Journal Repository (JR): Permanent Digital Archiving of SDI journals

SDI is happy to announce that all our journals are now permanently archived in Journal Repository (J...

SDI journal got 35th ranking in Publons

We are delighted to announce (as of 04/01/2016) that British Journal of Medicine and Medical Re...

Growth of SDI and world publication market

As of 2014, total 25,064 journals are competing in World market of journal publication. In 2011, tot...

Science (IF: 31) report confirmed the high standard of SDI journal

As per a recent report (Link) of Science journal (present Impact factor 31), one of our journal (Bri...

SDI introduced Post-publication peer review by its comment section

SDI journals encourage Post-publication peer review by its comment section   Policy details a...

SDI promotes transparent Advanced OPEN peer review

We have migrated to transparent and toughest ‘Advanced OPEN peer review’ system (...



SCIENCEDOMAIN Awards

  • No Awards listed.

Browser Compatibility : Mozila firefox, Google Crome and IE 7 & above. Creative Commons License Terms & Condition   |   Privacy Policy   |   Join Us   |   Help   |   Contact Us
© Copyright 2010-2018, SCIENCEDOMAIN international. All rights reserved.